1	Ti	+	

- 2 C-reactive protein guided use of procalcitonin in COVID-19
- **Authors** 3
- Rebecca Houghton¹, Nathan Moore¹, Rebecca Williams¹, Fatima El-Bakri¹, Jonathan Peters¹, Matilde Mori¹, 4
- 5 Gabrielle Vernet¹, Jessica Lynch¹, Henry Lewis¹, Maryanna Tavener¹, Tom Durham¹, Jack Bowyer¹, Kordo
- 6 Saeed^{2,3}, Gabriele Pollara^{4,5}
- 7 ¹Hampshire Hospitals NHS Foundation Trust, UK
- 8 ²University Hospital Southampton NHS Foundation Trust, UK
- 9 ³University of Southampton, School of Medicine, Southampton, UK
- 10 ⁴Royal Free London NHS Foundation Trust, UK
- ⁵University College London, UK 11
- Corresponding author 12
- Dr Gabriele Pollara, Division of Infection & Immunity, University College London, London, WC1E 6BT, UK. 13
- Email: g.pollara@ucl.ac.uk 14
- 16 Short title

15

- 17 CRP guided use of PCT in COVID-19
- Keywords 18
- 19 COVID-19; procalcitonin; C-reactive protein; antimicrobial stewardship;

Abstract

20

21

22

23

24

25

26

27

28

29

30

Low procalcitonin (PCT) concentrations (<0.5ng/mL) can facilitate exclusion of bacterial co-infection in viral infections, including COVID-19. However, costs associated with PCT measurement preclude universal adoption, indicating a need to identify settings where PCT provides clinical information beyond that offered by other inflammatory markers, such as C-reactive protein (CRP) and white cell count (WCC). In an unselected cohort of 299 COVID-19 patients, we tested the hypothesis that PCT<0.5ng/mL was associated with lower levels of CRP and WCC. We demonstrated that CRP values below the geometric mean of the entire patient population had a negative predictive value for PCT<0.5ng/mL of 97.6% and 100% at baseline and 48 hours into admission respectively, and that this relationship was not confounded by intensive care admission or microbiological findings. CRP-guided PCT testing algorithms can reduce costs and support antimicrobial stewardship strategies in COVID-19.

Main text

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Unnecessary antibiotic prescriptions during the COVID-19 pandemic will increase selection for antibiotic resistance (1). Optimising antimicrobial stewardship approaches in COVID-19 is a global priority, and a recent study has indicated that procalcitonin (PCT) <0.5ng/mL offered a high negative predictive value (>95%) for the presence of bacterial co-infections (2). Elevated PCT is associated more frequently with bacterial than viral infections (3), and thus low PCT can support cessation of antibiotic prescriptions in both COVID-19 and non-COVID-19 settings (4-8). Unlike the inflammatory markers C-reactive protein (CRP) and white cell count (WCC), PCT is not routinely measured (9), partly due to the costs associated with its testing (10,11). Elevations in PCT, CRP and WCC can be concordant (12), and therefore a key research question is to identify scenarios in which PCT provides clinical information beyond that offered by other inflammatory markers, in turn informing algorithms that avoid the expense of redundant PCT measurements. We identified 299 adult patients with compatible clinical syndromes for COVID-19 and SARS-CoV-2 confirmed on molecular testing, admitted to Hampshire Hospitals NHS Trust between 5th March and 26th April 2020. The measurement of PCT, CRP and WCC at baseline and daily during hospital admission was standard of care. We tested the hypothesis that PCT concentration was closely related to CRP or WCC levels, choosing PCT≥0.5ng/mL as threshold for the presence of bacterial pulmonary infection (4,7,8,13,14). PCT≥0.5ng/mL was associated with greater levels of CRP on admission and 48 hours into admission, independent of the need for intensive care unit (ICU) admission during the hospital stay (figs 1A+C). In contrast, PCT≥0.5ng/mL was associated with only a modestly greater WCC in non-ICU attending patients (fig 1B+D). Next, we used pairwise comparison to test the hypothesis that low levels of CRP/WCC could exclude PCT≥0.5 ng/ml. We used the geometric mean of CRP or WCC for the entire patient population at each timepoint as cut-offs for low and high levels of these markers. Strikingly, low CRP was strongly associated with PCT<0.5ng/mL (NPV 97.6% and 100% at baseline and 48 hours into admission respectively) (fig 1C). A similar relationship was observed for WCC, although with lower NPV (91.0% and 84.9% respectively) (fig 1D). Notably, patients with significant microbiological results, as previously defined (2), were not associated with elevated levels of any inflammatory marker (fig 1C+D) (9).

57

58

59

60

61

62

63

64

65

66

67

We demonstrate low CRP concentrations can predict low PCT values in COVID-19, precluding the cost of this test in approximately a third of patients. We acknowledge the retrospective, single-centre nature of the study, and the unspecified interval between symptom onset and hospital admission. However, these limitations are countered by the large, unselected populations, the consistent relationship between variables at both time points, and the independence from ICU admission status. The lack of association between PCT and microbiology results was notable and reminiscent of observations made in COVID-19 for other inflammatory markers (9). The diagnostic stewardship role for PCT in excluding bacterial co-infection at high CRP levels will need investigating through studies comparing COVID-19 with syndromically-defined bacterial pneumonia (9,15).

We declare no conflicts of interest.

Figure legend

68

69

70

71

72

73

74

75

76

77

78

Figure 1: Association between CRP or WCC and the concentration of PCT in COVID-19. Concentration of CRP (A) or enumeration of WCC (B) stratified by PCT concentration <0.5 or ≥0.5ng/mL and by requirement for ICU admission during hospital stay. Assessments were made on admission to hospital ("baseline") and 48 hours into hospital admission ("48h"). All p values derived using 2-tailed Mann-Whitney tests. Relationship between PCT and CRP concentration (C) or WCC (D). Scatter plot horizontal line represent PCT concentration cut-off (≥0.5ng/mL) and vertical line represents geometric mean of all patients at each timepoint, independent of PCT concentration. Total number of patients in each quadrant of scatter plot quantified in table below. Red dots and bracketed numbers reflect number of patients with significant microbiological findings. Sensitivity, specificity, PPV and NPV given for CRP (E) or WCC (F) to identify high or low PCT concentrations.

It is made available under a CC-BY-NC-ND 4.0

Houghton et al – CRP guided use of PCT in COVID-19

References

79

- 80 1. Nieuwlaat R, Mbuagbaw L, Mertz D, Burrows L, Bowdish DME, Moja L, et al. COVID-19 and
- Antimicrobial Resistance: Parallel and Interacting Health Emergencies. Clin Infect Dis. 2020 Jun 16;
- 82 2. May M, Chang M, Dietz D, Shoucri S, Laracy J, Sobieszczyk ME, et al. Limited Utility of Procalcitonin in
- 83 Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease
- 84 2019. Antimicrob Agents Chemother. 2021 Jan 25;
- 85 3. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a Marker of
- 86 Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis. 2017 Jul
- 87 15;65(2):183–190.
- 88 4. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of
- 89 procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a
- 90 randomised, controlled, open-label trial. Lancet Infect Dis. 2016 Jul;16(7):819–827.
- 91 5. Williams EJ, Mair L, de Silva Tl, Green DJ, House P, Cawthron K, et al. Evaluation of procalcitonin as a
- 92 contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. J Hosp
- 93 Infect. 2021 Jan 20;
- 94 6. Peters C, Williams K, Un EA, Little L, Saad A, Lendrum K, et al. Use of procalcitonin for antibiotic
- 95 stewardship in patients with COVID-19: A quality improvement project in a district general hospital.
- 96 Clin Med. 2020 Dec 18;
- 97 7. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AIR, Celinski M, Dushianthan A, et al. Procalcitonin as
- 98 an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist.
- 99 2020 Jul 25;22:782-784.
- 100 8. Drewett GP, Smibert OC, Holmes NE, Trubiano JA. The Use of Procalcitonin as an Antimicrobial
- Stewardship Tool and a Predictor of Disease Severity in COVID-19. Infect Control Hosp Epidemiol. 2021
- 102 Jan 25;1–5.


123

124

Jan;8(1):ofaa578.

103 Mason CY, Kanitkar T, Richardson CJ, Lanzman M, Stone Z, Mahungu T, et al. Exclusion of bacterial co-9. 104 infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J 105 Antimicrob Chemother. 2021 Jan 19; 106 10. Kip MMA, Kusters R, IJzerman MJ, Steuten LMG. A PCT algorithm for discontinuation of antibiotic 107 therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015 Jul 20;18(11):944-953. 108 Lubell Y, Do NTT, Nguyen KV, Ta NTD, Tran NTH, Than HM, et al. C-reactive protein point of care testing 109 11. in the management of acute respiratory infections in the Vietnamese primary healthcare setting - a 110 111 cost benefit analysis. Antimicrob Resist Infect Control. 2018 Oct 4;7:119. 112 12. Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, et al. Procalcitonin levels predict infectious 113 complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal 114 malignancy. Eur J Surg Oncol. 2016 Feb;42(2):234-243. 115 Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH, et al. Procalcitonin (PCT)-guided 13. antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab 116 117 Med. 2019 Aug 27;57(9):1308-1318. 118 Vaughn VM, Gandhi T, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric Antibacterial Therapy 14. 119 and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital 120 Cohort Study. Clin Infect Dis. 2020 Aug 21; Karaba SM, Jones G, Helsel T, Smith LL, Avery R, Dzintars K, et al. Prevalence of Co-infection at the Time 121 15. 122 of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open Forum Infect Dis. 2021

Figure 1



F

_				
E		Baseline	48h	
	Sensitivity	94.9%	100%	
	Specificity	42.8%	43.9%	
	PPV	25.7%	33.3%	
	NPV	97.6%	100%	

	Baseline	48h
Sensitivity	73.0%	70.3%
Specificity	54.3%	47.3%
PPV	24.1%	27.4%
NPV	91.0%	84.9%